Preview

Атеротромбоз

Расширенный поиск

ПРАСУГРЕЛ: ВОПРОСЫ ПРАКТИКУЮЩИХ ВРАЧЕЙ

https://doi.org/10.21518/2307-1109-2019-1-148-158

Полный текст:

Аннотация

.

Об авторах

О. О. Шахматова
Научно-исследовательский институт клинической кардиологии им. А.Л. Мясникова Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр кардиологии» Министерства здравоохранения
Россия

к.м.н., младший научный сотрудник отдела клинических проблем атеротромбоза

тел.: (495) 414-67-80

 



Е. П. Панченко
Научно-исследовательский институт клинической кардиологии им. А.Л. Мясникова Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр кардиологии» Министерства здравоохранения
Россия

д.м.н., профессор, руководитель отдела клинических проблем атеротромбоза

тел.: +7 (495) 150-44-19



Список литературы

1. Ibanez B., James S., Agewall S. et al. ESC Scientific Document Group, 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018 January 7;39(Issue 2):119–177. https: //doi.org/10.1093/eurheartj/ehx393.

2. Roffi M., Patrono C., Collet J.-P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016 January 14;37(Issue 3):267–315. https: //doi. org/10.1093/eurheartj/ehv320.

3. Neumann F.-J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019 January 7;40(Issue 2):87–165.

4. De Servi S., Goedicke J., Ferlini M. et al. Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location. Int J Cardiol. 2016;223:632-638.

5. Cuisset T., Cayla G., Quilici J. et al. Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. Int J Cardiol. 2013 Oct 3;168(3):2988-9.

6. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–260.

7. Silvain J., Kerneis M., Montalescot G. Potent P2Y12 inhibitors in low-risk patients: is there a medical need? J Am Coll Cardiol. 2016;67:614–617.

8. Dayoub E.J., Nathan A.S., Khatana S.A.M. et al. Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016. Circ Cardiovasc Interv. 2019 Jan;12(1):e007434. doi: 10.1161/CIRCINTERVENTIONS.118.007434.

9. Mangiacapra F., Pellicano M., Di Serafino L. et al. Platelet reactivity and coronary microvascular impairment after percutaneous revascularization instable patients receiving clopidogrel or prasugrel. Atherosclerosis. 2018 Nov;278:23-28.

10. Tomaniak M., Kołtowski Ł., Kochman J. et al. Can prasugrel decrease the extent of periprocedural myocardial injury during elective percutaneous coronary intervention? Pol Arch Intern Med. 2017 Nov 30;127(11):730-740.

11. ClinicalTrials.gov. Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention; NCT02548611. https://clinicaltrials.gov/ct2/show/NCT02548611.

12. Kimura T., Isshiki T., Ogawa H. et al. Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention. J Atheroscler Thromb. 2015;22(6):557-69.

13. Toba T., Shinke T., Otake H. et al. Impact of dual antiplatelet therapy with adjusted-dose prasugrel on midterm vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents. Heart Vessels. 2019 Jan 1. doi: 10.1007/s00380-018-1322-2.

14. Sarafoff N., Martischnig A., Wealer J. et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060–2066.

15. Gibson C.M., Mehran R., Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–2434.

16. Guimarães P.O., Zakroysky P., Goyal A. et al. Usefulness of Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Myocardial Infarction. American Journal of Cardiology. 2019;123(Issue 1):12–18. doi:10.1016/j.amjcard.2018.09.031.

17. Verlinden N.J., Coons J.C., Iasella C.J., Kane-Gill S.L. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel. J Cardiovasc Pharmacol Ther. 2017 Nov;22(6):546-551.

18. Sra S., Tan M.K., Mehta S.R. et al. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. Am Heart J. 2016 Oct;180:82-9.

19. ClinicalTrials.gov. Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI). https://clinicaltrials. gov/ct2/show/NCT02866175.

20. Sibbing D., Aradi D., Jacobshagen C. et al. TROPICALACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial. Lancet. 2017;390:1747–1757.

21. Шахматова О.О., Комаров А.Л. Прасугрел в лечении пациентов с острым коронарным синдромом и чрескожным коронарным вмешательством: современное состояние проблемы. Атеротромбоз. 2018;1:52-66.

22. Cuisset T., Deharo P., Quilici J. et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070–3078.

23. Cerrato E., Bianco M., Bagai A. et al. Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. Int J Cardiol Heart Vasc. 2018 Dec 8;22:39-45.

24. Doherty J.U., Gluckman T.J., Hucker W.J. et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology. 2017;69(Issue 7):871-898.

25. Godier A., Garrigue D., Lasne D. et al. Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR). Arch Cardiovasc Dis. 2019 Jan 5. pii: S1875-2136(18)30197-9.

26. Zafar M.U., Santos-Gallego C., Vorchheimer D.A. et al. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost. 2013;11:100-106.

27. O’Connor S.A., Amour J., Mercadier A. et al. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circ Cardiovasc Interv. 2015;8:e002786-6.

28. Hobl E.L., Reiter B., Schoergenhofer C. et al. Morphine interaction with prasugrel: A double-blind, crossover trial in healthy volunteers. Clin Res Cardiol. 2016;105:349-55.

29. Parodi G., Bellandi B., Xanthopoulou I. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary PCI. Circ Cardiovasc Interv. 2015:1593.

30. Johnson T.W., Mumford A.D., Scott L.J. et al. A study of platelet inhibition, using a ‘point of care’ platelet function test, following primary percutaneous coronary intervention for ST-elevation myocardial infarction [PINPOINT-PPCI]. PloS One. 2015;10:e0144984.

31. Xanthopoulou I., Davlouros P., Tsigkas G. et al. Factors affecting platelet reactivity 2 hours after p2y12 receptor antagonist loading in primary percutaneous coronary intervention for ST-elevation myocardial infarction-impact of pain-to-loading time. Circ J. 2016;80:442-9.

32. Ibrahim K., Shah R., Goli R.R. et al. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial. Thromb Haemost. 2018;118(8):1409-1418.

33. Ather A., Beavers C.J. Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity. Current Vascular Pharmacology. 2019;17:127.


Для цитирования:


Шахматова О.О., Панченко Е.П. ПРАСУГРЕЛ: ВОПРОСЫ ПРАКТИКУЮЩИХ ВРАЧЕЙ. Атеротромбоз. 2019;(1):148-158. https://doi.org/10.21518/2307-1109-2019-1-148-158

For citation:


Shakhmatova O.O., Panchenko E.P. PRASUGREL: FREQUENTLY ASKED QUESTIONS FROM PRACTITIONERS. Atherothrombosis. 2019;(1):148-158. (In Russ.) https://doi.org/10.21518/2307-1109-2019-1-148-158

Просмотров: 79


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)